TR200102801T2 - Solid tümörlerin tedavisine yönelik yöntem ve bileşimler - Google Patents

Solid tümörlerin tedavisine yönelik yöntem ve bileşimler

Info

Publication number
TR200102801T2
TR200102801T2 TR2001/02801T TR200102801T TR200102801T2 TR 200102801 T2 TR200102801 T2 TR 200102801T2 TR 2001/02801 T TR2001/02801 T TR 2001/02801T TR 200102801 T TR200102801 T TR 200102801T TR 200102801 T2 TR200102801 T2 TR 200102801T2
Authority
TR
Turkey
Prior art keywords
compositions
treatment
methods
solid tumors
tumor
Prior art date
Application number
TR2001/02801T
Other languages
English (en)
Turkish (tr)
Inventor
Dang Wenbid
Jr. Robert Garver I.
Original Assignee
Guilford Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals, Inc. filed Critical Guilford Pharmaceuticals, Inc.
Publication of TR200102801T2 publication Critical patent/TR200102801T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
TR2001/02801T 1999-03-26 2000-03-20 Solid tümörlerin tedavisine yönelik yöntem ve bileşimler TR200102801T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/276,866 US6537585B1 (en) 1999-03-26 1999-03-26 Methods and compositions for treating solid tumors

Publications (1)

Publication Number Publication Date
TR200102801T2 true TR200102801T2 (tr) 2002-04-22

Family

ID=23058398

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02801T TR200102801T2 (tr) 1999-03-26 2000-03-20 Solid tümörlerin tedavisine yönelik yöntem ve bileşimler

Country Status (17)

Country Link
US (2) US6537585B1 (https=)
EP (1) EP1185249B1 (https=)
JP (2) JP2002540137A (https=)
KR (1) KR20010111578A (https=)
CN (1) CN1367684A (https=)
AT (1) ATE306251T1 (https=)
AU (1) AU778279B2 (https=)
BR (1) BR0009213A (https=)
CA (1) CA2368621C (https=)
CZ (1) CZ20013260A3 (https=)
DE (1) DE60023138T2 (https=)
HU (1) HUP0201436A3 (https=)
IL (1) IL145492A0 (https=)
NO (1) NO20014662L (https=)
PL (1) PL351280A1 (https=)
TR (1) TR200102801T2 (https=)
WO (1) WO2000057852A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU2001270310A1 (en) * 2000-07-07 2002-01-21 Guilford Pharmaceuticals Inc. Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
AU2001280597A1 (en) * 2000-07-17 2002-01-30 Guilford Pharmaceuticals Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US20020198135A1 (en) * 2000-10-12 2002-12-26 Wenbin Dang Compositions for release of radiosensitizers, and methods of making and using the same
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
WO2003000776A1 (en) * 2001-05-14 2003-01-03 Johns Hopkins Singapore Pte Ltd Biodegradable polyphosphoramidates for controlled release of bioactive substances
US7345138B2 (en) * 2001-05-14 2008-03-18 Johns Hopkins Singapore Pte Ltd. Biodegradable polyphosphates for controlled release of bioactive substances
WO2003007914A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
US20030134892A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of head and neck cancers, and methods of making and using the same
AU2003202255A1 (en) * 2002-01-09 2003-07-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
AU2003216424A1 (en) 2002-02-25 2003-10-08 Guilford Pharmaceuticals, Inc. Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
SI1677828T1 (sl) * 2003-10-21 2013-04-30 Psimedica Limited Kompozitni material, ki vsebuje porozen polprevodnik impregniran z organsko substanco
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
WO2006002399A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
EP1835931A4 (en) * 2004-12-06 2008-12-17 Sciclone Pharmaceuticals Inc ALPHA THYMOSINE PEPTIDES AS CANCER VACCINE ADJUVANTIES
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2618807C (en) * 2005-08-12 2015-01-06 University Health Network Methods and devices for lymphatic targeting
GB0525864D0 (en) * 2005-12-20 2006-02-01 Novartis Ag Organic compounds
EP3047860B1 (en) 2006-07-20 2024-08-28 OrbusNeich Medical Pte. Ltd. Bioabsorbable polymeric composition for a medical device
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8691321B2 (en) 2006-10-20 2014-04-08 Orbusneich Medical, Inc. Bioabsorbable polymeric composition and medical device background
CN101390828B (zh) * 2007-02-12 2010-06-09 济南康泉医药科技有限公司 同载抗代谢类药物和增效剂的抗癌组合物
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CA2763365C (en) 2009-05-29 2016-09-13 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
ES2362525B8 (es) 2009-10-08 2013-01-03 Azurebio, S.L. Formulación de medicamentos en forma de agujas percutaneas penetrantes.
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
CN104884065B (zh) 2012-09-21 2019-01-01 强烈治疗剂公司 治疗癌症的方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9545447B2 (en) 2013-01-04 2017-01-17 The Texas A&M University System Polymer-drug systems
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
EP3615145B1 (en) 2017-06-09 2024-05-15 Crititech, Inc. Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
JP2022508807A (ja) 2018-10-16 2022-01-19 ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド 腫瘍内注射製剤
US11752165B2 (en) 2020-04-13 2023-09-12 US Nano Food & Drug, Inc Basic chemotherapeutic intratumour injection formulation
GB2623319A (en) 2022-10-11 2024-04-17 Af Chempharm Ltd Method of synthesis of chloro-oxo-dioxaphospholane oxides and derivates

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271329A (en) 1958-09-19 1966-09-06 Eastman Kodak Co Method for producing polymers derived from phosphites and glycols
US3442982A (en) 1965-10-15 1969-05-06 Weston Chemical Corp Polyphosphites of 2,2-dimethyl-3-hydroxypropyl - 2 - dimethyl - 3-hydroxypropionate
FR2219193B1 (https=) 1973-02-28 1976-05-21 Rhone Poulenc Sa
US3932566A (en) 1974-09-16 1976-01-13 Celanese Corporation Phosphonate polymers
US4100354A (en) 1976-08-05 1978-07-11 Owens-Corning Fiberglass Corporation Terephthalate ester polyols
US4259222A (en) 1978-08-16 1981-03-31 Basf Wyandotte Corporation Linear saturated polyesters of phosphoric acid and halogenated diols as flame-retardant additives and coatings
DE2925206A1 (de) 1979-06-22 1981-01-29 Bayer Ag Aromatische polyesterphosphonate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung thermoplastischer formkoerper
FR2498612A1 (fr) 1981-01-26 1982-07-30 Peters Ligatures Nouveaux polymeres insolubles a biodegradabilite reglable a volonte, leurs procedes de preparation et leur application en tant que biomateriaux
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4474937A (en) 1983-10-03 1984-10-02 The Dow Chemical Company Phosphorus-modified polyestercarbonate resins
US4481353A (en) 1983-10-07 1984-11-06 The Children's Medical Center Corporation Bioresorbable polyesters and polyester composites
US4746462A (en) 1985-02-21 1988-05-24 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Phosphoric ester compound
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5256765A (en) 1989-03-09 1993-10-26 The Johns Hopkins University School Of Medicine Biodegradable poly(phosphate esters)
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
NZ265555A (en) 1993-04-19 1997-09-22 Medisorb Technologies Internat Biodegradable microparticle compositions of antisense oligodeoxyribonucleotides
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
JPH09507233A (ja) 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
DE4404365A1 (de) 1994-02-11 1995-08-17 Cassella Ag Phosphin- und phosphonsäuregruppenhaltige Polykondensate
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5637085A (en) 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
US6111033A (en) 1996-04-23 2000-08-29 Kinerton, Limited Acidic polylactic polymers
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
PL335891A1 (en) 1997-03-27 2000-05-22 Baker Norton Pharma Methods of and compositions for treating ovarian carcinoma
UA54505C2 (uk) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
ATE279461T1 (de) 1997-04-03 2004-10-15 Guilford Pharm Inc Bioabbaubare terephthalat polyester-polyphosphat polymere, zusammensetzungen, gegenstände und verfahren für ihre herstellung und verwendung
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
NZ501184A (en) 1997-04-30 2002-08-28 Guilford Pharm Inc Biodegradable poly (phosphodiester) compositions that degrade in vivo into non-toxic residues
WO1998058012A1 (en) 1997-06-18 1998-12-23 Guilford Pharmaceuticals Inc. Two-stage solution polymerization of high molecular weight poly(phosphoesters)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
WO2000019976A2 (en) 1998-10-02 2000-04-13 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them
US6419709B1 (en) * 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6350464B1 (en) 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
AU2001270310A1 (en) 2000-07-07 2002-01-21 Guilford Pharmaceuticals Inc. Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
AU2001280597A1 (en) * 2000-07-17 2002-01-30 Guilford Pharmaceuticals Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US20020198135A1 (en) * 2000-10-12 2002-12-26 Wenbin Dang Compositions for release of radiosensitizers, and methods of making and using the same
WO2003007914A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
US20030134892A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of head and neck cancers, and methods of making and using the same

Also Published As

Publication number Publication date
AU3762500A (en) 2000-10-16
BR0009213A (pt) 2002-04-16
CN1367684A (zh) 2002-09-04
US7101568B2 (en) 2006-09-05
NO20014662D0 (no) 2001-09-25
DE60023138D1 (de) 2006-02-23
PL351280A1 (en) 2003-04-07
CA2368621A1 (en) 2000-10-05
US6537585B1 (en) 2003-03-25
US20030203033A1 (en) 2003-10-30
WO2000057852A2 (en) 2000-10-05
ATE306251T1 (de) 2005-10-15
CZ20013260A3 (cs) 2002-01-16
KR20010111578A (ko) 2001-12-19
HUP0201436A2 (en) 2002-09-28
CA2368621C (en) 2010-05-25
DE60023138T2 (de) 2006-08-17
IL145492A0 (en) 2002-06-30
AU778279B2 (en) 2004-11-25
EP1185249B1 (en) 2005-10-12
JP2011219483A (ja) 2011-11-04
NO20014662L (no) 2001-11-20
HUP0201436A3 (en) 2003-04-28
WO2000057852A3 (en) 2001-02-15
EP1185249A2 (en) 2002-03-13
JP2002540137A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
TR200102801T2 (tr) Solid tümörlerin tedavisine yönelik yöntem ve bileşimler
TR200102012T2 (tr) Yumurtalık kanserinin tedavi yöntemleri, poli (fosfoester) bileşimler ile bunlara ait biyolojik olarak parçalanabilir maddeler.
NO20005452D0 (no) Matrise tildannet fra polymer- og hydrofobe forbindelser for bruk i medikamentavlevering
BR0207378A (pt) Tratamento de câncer
DE69715670D1 (de) Konditionierende shampoozusammensetzung
BR0016828A (pt) Polìmeros superabsorventes
ID30325A (id) Komposisi polimer emisi rendah
WO2001091725A3 (en) Biologically useful polyphosphates
ES2179646T3 (es) Revestimiento que libera un agente bioactivo.
TR199801356A2 (xx) Bir y�zey-aktif veya gerilim-aktif yap�s� olan bir kopolimerin da��t�c� madde ve/veya ���t�c� yard�mc�s� olarak kullan�m�.
PT1028753E (pt) Libertacao de moleculas de poli(etilenoglicol)-conjugado a partir de hidrogeles degradaveis
PL362136A1 (en) Oxidising composition for treating keratinous materials based on amphiphilic polymers of at least an ethylenically unsaturated monomer with sulphonic group and comprising a hydrophobic part
WO2003072754A3 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
TR199903009T2 (xx) Temizlik bile�imleri
AU2002218745A1 (en) Particulate vectors for improving oral absorption of active principles
AU6696300A (en) Water-soluble granules of salen-type manganese complexes
MX290138B (es) Composicion acuosa gelificada que comprende un copolimero de bloque que contiene por lo menos un bloque hidrosoluble y un bloque hidrofobico.
DE60131991D1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
EP0727984A4 (en) PREPARATION WITH CONTROLLED RELEASE
WO2001044307A3 (en) Degradable poly(vinyl alcohol) hydrogels
EP2269580A3 (en) Compositions comprising camptothecins in microspheres
CO5251434A1 (es) Composicion de liberacion controlada
BR9710940A (pt) Processo para aumentar a taxa de solubilidade de um filme solúvel em água
ES2178631T3 (es) Composicion a base de un oligomero y un polimero, inyectable y biodegradable.
TR200001724T2 (tr) 5-HT1F Agonistleri